Navigation Links
Comparing combination therapies for advanced head and neck cancer shows no improvement
Date:3/7/2013

ncology.

Dr. Hayes, associate professor of medicine, explains, "There has been great enthusiasm and some confusion about the combinations of chemotherapy and biologic therapy such as EGFR inhibitors in conjunction with radiation in the treatment of squamous cell carcinomas of the head and neck. For the moment, the data are clearly showing no added benefit. Since the study was initially designed, it is interesting to note that novel theories have emerged about subgroups of patients who might be more likely to benefit from the specific therapies under consideration. Future investigations will clearly rely more on patients selected by the molecular tumor characteristics."

Between December 2006 and October 2011, 204 patients with locally advanced SCCHN were recruited to the study. Participants were assigned to receive either cisplatin and radiotherapy or the same chemoradiotherapy with Erlotinab.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina Health Care
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. The ethics of access: Comparing 2 federal health care reform efforts
2. New drug combination could prevent head and neck cancer in high-risk patients
3. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
4. People with HIV hospitalized less often since combination antiretroviral drug therapy introduced
5. Combination of imaging exams improves Alzheimers diagnosis
6. Drug combination acts against aggressive chronic lymphocytic leukemia
7. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
8. Combination treatment may improve survival of breast cancer patients with brain metastases
9. Drug combination against NRAS-mutant melanoma discovered
10. Combination peptide therapies might offer more effective, less toxic cancer treatment
11. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Comparing combination therapies for advanced head and neck cancer shows no improvement
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... Foundation scientists examined the implications for cultural diversity ... rehabilitation. The article by Anthony Lequerica, PhD, and ... acquired brain injury (ABI) rehabilitation (doi:10.3233/NRE-141079) was ... and Krch are research scientists in Traumatic Brain ... for the Northern New Jersey TBI Model System. ...
(Date:8/27/2014)... significantly improve musculoskeletal and overall health, and minimize or ... of the latest research on senior athletes (ages 65 ... Journal of the American Academy of Orthopaedic Surgeons ... aging causes an inevitable deterioration of the body and ... of related injuries such as sprains, strains and fractures; ...
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
Breaking Medicine News(10 mins):Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Lifetime of fitness: A fountain of youth for bone and joint health? 2
... implants created using stem cells can only be constructed ... before the almost inevitable need for total joint replacement. ... investigating the possibilities of a biologically-engineered synthetic liquid polymer ... offering a one stop, permanent solution. ...
... caregivers to hospital patients, coordinating and providing direct care and delivering ... ensure that each of its patient-care units has an adequate number ... number of hours nurses work known as the "target level" ... flow of patients and their need for care. Too many nurses ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... target levels in a large hospital, more patients died, a ... an era of nursing shortages and cost-cutting, in that the ... authors of the research, appearing in the March 17 issue ...
... By Amanda Gardner HealthDay Reporter , ... the tsunami that devastated the nuclear complex in Japan ... that any radiation from the unfolding disaster across the ... say. The chances of any radioactive plume reaching ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... treatment to show a benefit for women with a rare ... even a treatment. The drug, sirolimus (Rapamycin), improved both ... lymphangioleiomyomatosis, or LAM, according to a study published online March ...
... recent study from North Carolina State University shows that while ... has grown, fund support for park operations has been significantly ... growth endangers the more than $20 billion in economic impact ... the reduction in general-fund support for operations puts stress on ...
Cached Medicine News:Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4Health News:Transplant Drug May Fight Rare Lung Disorder 2Health News:Transplant Drug May Fight Rare Lung Disorder 3Health News:Study shows attendance at state parks grows, even as funding decreases 2
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that certain members of the executive ... Conference to be held September 8-10, 2014 in ... Chief Executive Officer and President, is scheduled to present ... at 10:55 a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... ultra versatile model angulates for vascular ... the height of the support leg, ... post, or double tee foot. Add ... comfort and stability. A convenient bracket ...
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... OL1000 Bone Growth Stimulators are portable, battery-powered ... noninvasive treatment of an established nonunion fracture ... and flat bones. , ... of healing of 60.7% in patients with ...
... The EBI OsteoGen surgically implanted bone growth ... of nonunions when surgery is already planned or ... the OsteoGen is totally surgically implanted, patients are ... site 24 hours a day for up to ...
Medicine Products: